New combo therapy aims to tackle Hard-to-Treat lung cancer

NCT ID NCT06930794

Recruiting now Disease control Sponsor: Beijing Pearl Biotechnology Limited Liability Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with a specific type of advanced lung cancer (MET-positive non-squamous non-small cell lung cancer) live longer without their cancer growing. About 300 adults who have not had prior treatment will be randomly assigned to receive either the combination or chemotherapy alone. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vebreltinib (a targeted drug) combined with platinum-based chemotherapy (pemetrexed plus carboplatin or cisplatin)
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with MET-positive advanced lung cancer, potentially slowing disease progression better than chemotherapy alone.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may cause side effects like those seen with other targeted therapies, and not all participants may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100021, China
Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.